Screener
Kyverna Therapeutics, Inc. KYTX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities | ||
| Purchases of available-for-sale marketable securities | (115,901) | (81,122) |
| Proceeds from maturities of available-for-sale marketable securities | 65,700 | 86,700 |
| Net cash provided by (used in) investing activities | (50,201) | 5,578 |
| Cash flows from financing activities | ||
| Proceeds from exercise of common stock options | 243 | 3 |
| Principal paid on finance lease liabilities | (86) | (341) |
| Payments for offering costs | (69) | (76) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s investing cash flow?
- Kyverna Therapeutics, Inc. (KYTX) reported investing cash flow of -$50.2M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Kyverna Therapeutics, Inc.'s investing cash flow decreased by 1000.0% year-over-year, from $5.58M to -$50.2M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Kyverna Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude